Coronavirus vaccine by Oxford-AstraZeneca produces immune response among adults

Coronavirus vaccine by Oxford-AstraZeneca produces immune response among adults

Guy Faulconbridge, Kate Kelland and Kate Holton

Posted October 26, 2020 7:22 am


Updated October 26, 2020 2:10 pm

Coronavirus: Trudeau announces agreement with AstraZeneca for 20 million vaccine doses if trials successful

WATCH: Trudeau announces agreement with AstraZeneca for 20 million vaccine doses if trials successful

  • comments

    Leave a comment

  • whatsapp

    Share this item via WhatsApp

  • more

    Share this item

  • more

    Share this item

Smaller font
Descrease article font size

Larger font
Increase article font size

  • Share this item via WhatsApp


  • Share this item on Pinterest


  • Share this item on LinkedIn


  • Share this item on Reddit


  • Copy article link

    Copy link

The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.

A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, hammered the global economy and shuttered normal life across the world.

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman told Reuters.

“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, referring to the technical name of the vaccine.

Read more:
AstraZeneca resumes U.S. coronavirus vaccine trial, Johnson & Johnson to follow

Story continues below advertisement

The news that older people get an immune response from the vaccine is positive because the immune system weakens with age and older people are those most at risk of dying from the virus.

The Financial Times reported earlier that the vaccine, being developed by Oxford and AstraZeneca, triggers protective antibodies and T-cells in older age groups – among those most at risk from the virus.

The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech’s candidate.

If it works, a vaccine would allow the world to return to some measure of normality after the tumult of the pandemic.

Canada signs new coronavirus vaccine deals

Canada signs new coronavirus vaccine deals

Immunogenicity blood tests carried out on a subset of older participants echo data released in July which showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55, the Financial Times reported.

Trending Stories

  • Patty Hajdu responds to Twitter photo, says she only removes mask to eat, drink

  • Cars can’t crush the diabolical ironclad beetle, 2020’s latest horror

Story continues below advertisement

Details of the finding are expected to be published shortly in a clinical journal, the FT said. It did not name the publication.


British Health Secretary Matt Hancock said a vaccine was not yet ready though he was preparing logistics for a possible roll out.

“I would expect the bulk of the roll out to be in the first half of next year,” Hancock told the BBC.

Coronavirus: WHO scientist calls AstraZeneca vaccine trial a ‘wake-up call’

Coronavirus: WHO scientist calls AstraZeneca vaccine trial a ‘wake-up call’

Asked if some people could receive a vaccine this year he told the BBC: “I don’t rule that out but that is not my central expectation.”

“We want to be ready in case everything goes perfectly but it’s not my central expectation that we’ll be doing that this year, but the program is progressing well, we’re not there yet,” Hancock said.

Story continues below advertisement

Called AZD1222 or ChAdOx1 nCoV-19, the vaccine was developed by Oxford University scientists and licensed to AstraZeneca in April, which took on the task of scaling trials and production.

The vaccine is likely to provide protection for about a year, CEO Pascal Soriot said in June.

Read more:
Coronavirus vaccine storage issues could leave 3 billion without access

The British drugmaker has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.

AstraZeneca resumed the U.S. trial of the experimental vaccine after approval by U.S. regulators, the company said on Friday.

Staff at a London hospital trust have been told to be ready to receive the first batches of the vaccine being developed by the University of Oxford and AstraZeneca Plc, The Sun newspaper reported on Monday.

The Sun said the hospital, which was not identified, was told to prepare for the vaccine from the “week commencing the 2 November.”

View link »

© 2020 Reuters

Leave a comment


CoronavirusCOVID-19VaccineCoronavirus VaccineCOVID-19 Vaccinecovid vaccineAstraZenecaOxford UniversityAstraZeneca vaccineOxford vaccineastrazeneca covid 19 vaccineastrazeneca oxford

Leave a comment


More from Global News

  • North York General Hospital declares coronavirus outbreak in surgical program

  • Saint John council reunited in newly-renovated chambers


View link »

Tagged , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *